Protecting our most vulnerable from the risk of pneumococcal disease

+Practice

VACCINES

Protecting our most vulnerable from the risk of pneumococcal disease

6 July 2022

By Shelley Kininmonth and Anna Howe

Wednesday 6 July 2022, 12:30 AM

Unvaccinated children are vulnerable to the potentially devasting impact of pneumococcal disease [Image: IMAC]

Identifying those at highest risk of invasive pneumococcal disease is vital, so they can be protected with the appropriate vaccination schedule

Key points, People at highest risk of pneumococcal disease are under five years of age; older people; the immunocompromised; those with respiratory or cardiovascu, Pract Green w Pale Yellow

Paediatrics

References

Van Buynder PA. Reducing pneumococcal risk in people aged 65 years and over. Med Today 2019;20(2 Suppl):11–4.
ESR. Annual Notifiable Disease Tables. https://surv.esr.cri.nz/surveillance/annual_diseasetables.php
Eichler N, Reynolds E, Jackson C, et al. Invasive pneumococcal disease and serotype emergence in the Auckland region during the vaccine era 2009–16. J Prim Health Care 2019;11(1):24–31.
Manoharan A, Jayaraman R. Pneumococcal vaccines. Indian J Med Microbiol 2018;36(4):465–74.
Ministry of Health. Pneumococcal disease. Immunisation Handbook 2020. https://www.health.govt.nz/our-work/immunisation-handbook-2020/16-pneumococcal-disease
Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One 2017;12(1):e0169368.
Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis 2020;99:204–13.

How to Treat

+How to treat

COPD: Prevent, treat and comfort

Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management

Wednesday 26 March 2025, 12:50 AM